Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Bhag Karamchandani who wrote (4310)	5/15/1998 4:34:00 PM
From: Peter Singleton	of 6136

Bhag, MATX's results were a little different ... interim analyses of two separate PII trials in liver cancer (primary and metastatic, I believe) indicated at least 4 of 17 patients in each trial met the end point of response, which was defined as 50% increase in tumor volume or 30% increase in necrotic tumor tissue. This was the criteria for continuing enrollment to c. 40 patients in each trial. The Intradose product is a chemotherapeutic drug (cisplatin), a vaso-constrictor (epinephrine) and a bio-degradable protein matrix (collagen). not a direct competitor with AGPH, but of course in the cancer space. Peter

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next